Journal article
Assessing genital human papillomavirus genoprevalence in young Australian women following the introduction of a national vaccination program
SL Osborne, SN Tabrizi, JML Brotherton, AM Cornall, JD Wark, CD Wrede, Y Jayasinghe, DM Gertig, MK Pitts, SM Garland, M Saville, J Pyman, J Tan, ET Callegari
Vaccine | Published : 2015
Abstract
Objectives: Following the implementation of Australia's National HPV Vaccination Program in April 2007, this study evaluated the prevalence of vaccine-targeted human papillomavirus (HPV) genotypes (HPV 6, 11, 16, 18) amongst vaccine-eligible young women. Methods: Between September 2011 and August 2013, women from Victoria, Australia aged 18-25 were recruited through targeted advertising on the social networking website Facebook. Participants completed an online questionnaire, and sexually active women were asked to provide a self-collected vaginal swab for HPV deoxyribonucleic acid (DNA) detection and genotyping. Samples positive for HPV were genotyped using the Linear Array HPV genotyping t..
View full abstractGrants
Funding Acknowledgements
We gratefully acknowledge the Victorian Cancer Agency as our funding body. We thank Elisa Young for initial project management and co-ordination and Adele Rivers for participant recruitment and management. We also acknowledge Houda Abdo and Angela Hurley for completing all HPV genotyping analysis and Athena Costa for assisting with the manuscript submission. We thank the NHVPR staff who assisted with the study, particularly Daniela Petrovski and Jennifer Nguyen. The NHVPR is owned by the Australian Government Department of Health and operated by the VCS.Conflict of interest statement: SMG has received advisory board fees and grant support from CSL and GlaxSmithKline, and lecture fees from Merck, GSK and Sanofi Pasteur; in addition, S.M.G. has received funding to conduct HPV vaccine studies for MSD and GSK. S.M.G. is a member of the Merck Global Advisory Board as well as the Merck Scientific Advisory Committee for HPV. JMLB, DMG MS and SMG were partner investigators on an Australian Research Council Linkage Grant 2008-2011 on which CSL Biotherapies was a partner organisation. S.M.G., S.N.T., J.M.L.B. are partner investigators with CSL Biotherapies for a cervical cancer genotyping study.